GlassScriptPhysician profile
Susan J Souther
NPI 1861482077
$7,870.55
in general payments reported to CMS, 2019-2025
38 companies · $856 in 2025
The $856 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,007 · 2020: $760 · 2021: $1,039 · 2022: $1,869 · 2023: $1,388 · 2024: $952 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,095 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,095.39 |
| Education | $100.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,343.52 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $1,048.57 | 2019-2025 | |
| Edwards Lifesciences Corporation | $618.83 | 2019-2025 | Sapien 3 Ultra Resilia |
| Actelion Pharmaceuticals US, INC. | $600.95 | 2019-2025 | Uptravi, Opsumit |
| Janssen Pharmaceuticals, INC | $444.68 | 2019-2022 | |
| Pfizer INC. | $410.56 | 2019-2024 | |
| Abiomed | $390.58 | 2019-2023 | Impella |
| Abbott Laboratories | $349.66 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.52 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $274.03 | 2019-2024 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $263.00 | 2019-2024 | |
| Amgen INC. | $260.29 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $241.49 | 2020-2025 | Watchman Flx, Watchman, General - Therapies |
| Merck Sharp & Dohme LLC | $220.10 | 2021-2023 | Verquvo |
| Amarin Pharma, INC. | $132.99 | 2021-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $111.83 | 2020-2023 | Farxiga |
| Medtronic, INC. | $106.38 | 2021-2023 | Linq II |
| Scpharmaceuticals INC. | $84.13 | 2023-2024 | |
| Baxter Healthcare | $81.63 | 2023 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Medtronic Vascular, INC. | $73.77 | 2020 | |
| Esperion Therapeutics, INC. | $70.16 | 2021-2024 | Nexletol |
| Irhythm Technologies, INC. | $55.13 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $46.72 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $40.58 | 2023 | Arcalyst |
| Inspire Medical Systems, INC. | $39.27 | 2025 | Inspire |
| Cvrx, INC. | $33.66 | 2024 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $30.70 | 2022-2023 | |
| Philips North America LLC | $27.79 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Portola Pharmaceuticals, LLC | $22.15 | 2019 | |
| Daiichi Sankyo INC. | $20.31 | 2024 | Injectafer |
| Novo Nordisk INC | $20.14 | 2023 | Wegovy |
| Biotronik INC. | $19.89 | 2020 | |
| Elutia, INC. | $16.99 | 2019 | |
| Inogen, INC. | $15.82 | 2022 | |
| Altathera Pharmaceuticals LLC | $15.05 | 2025 | Sotalol Hydrochloride |
| Cardiovascular Systems INC. | $12.73 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.10 | 2022 | |
| Medtronic USA, INC. | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Souther listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.